HBW Insight Podcasts https://insights.citeline.com/hbw-insight/ en All rights reserved HBW Insights’ Over the Counter podcast, hosted by David Ridley, helps OTC professionals navigate the fast-changing consumer health and wellness market. Featuring expert journalists and industry voices, episodes unpack regulation, innovation, marketing and retail trends. Stay ahead at https://insights.citeline.com/hbw-insight for newsletters and insight on the global self-care market each week. https://megaphone.imgix.net/podcasts/2402cd7a-31a9-11f1-8b30-27b1aedb6ca4/image/24f74877267933c1ebeab5120f697d3b.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress HBW Insight Podcasts https://insights.citeline.com/hbw-insight/ episodic Norstella HBW Insights’ Over the Counter podcast, hosted by David Ridley, helps OTC professionals navigate the fast-changing consumer health and wellness market. Featuring expert journalists and industry voices, episodes unpack regulation, innovation, marketing and retail trends. Stay ahead at https://insights.citeline.com/hbw-insight for newsletters and insight on the global self-care market each week. HBW Insights’ Over the Counter podcast, hosted by David Ridley, helps OTC professionals navigate the fast-changing consumer health and wellness market. Featuring expert journalists and industry voices, episodes unpack regulation, innovation, marketing and retail trends. Stay ahead at https://insights.citeline.com/hbw-insight for newsletters and insight on the global self-care market each week.

]]> Norstella webpubs@citeline.com The Dos And Don’ts Of Health Literacy, With Self-Care Forum’s Trevor Gore Health literacy is a phrase you hear a lot in consumer health at the moment, but it's not always clear what people mean by it, or what a company is actually supposed to do about it. In this episode of Over the Counter, HBW Insight talks to Trevor Gore, a trustee of the Self-Care Forum who spent more than two decades at Reckitt and now looks at healthcare through behavioural science. Gore's argument is that most companies treat health literacy as a readability job, making labels and leaflets easier to follow, when the harder work is changing what people do: helping them recognize symptoms, understand risk and act on it. We discuss the three levels of health literacy, the gap between what people intend to do and what they actually do, the line between educating and promoting, and why awareness on its own buys you almost nothing. Timestamps 3:00 – Introductions 5:00 – What is health literacy? 7:00 – What has health literacy become so important? 15:30 – What are CHC companies doing well? 25:00 – The role of behavioural science 29:00 – What do you need to do now? Tue, 14 Jul 2026 06:27:00 -0000 full Norstella Health literacy is a phrase you hear a lot in consumer health at the moment, but it's not always clear what people mean by it, or what a company is actually supposed to do about it. In this episode of Over the Counter, HBW Insight talks to Trevor Gore, a trustee of the Self-Care Forum who spent more than two decades at Reckitt and now looks at healthcare through behavioural science. Gore's argument is that most companies treat health literacy as a readability job, making labels and leaflets easier to follow, when the harder work is changing what people do: helping them recognize symptoms, understand risk and act on it. We discuss the three levels of health literacy, the gap between what people intend to do and what they actually do, the line between educating and promoting, and why awareness on its own buys you almost nothing. Timestamps 3:00 – Introductions 5:00 – What is health literacy? 7:00 – What has health literacy become so important? 15:30 – What are CHC companies doing well? 25:00 – The role of behavioural science 29:00 – What do you need to do now? Health literacy is a phrase you hear a lot in consumer health at the moment, but it's not always clear what people mean by it, or what a company is actually supposed to do about it. In this episode of Over the Counter, HBW Insight talks to Trevor Gore, a trustee of the Self-Care Forum who spent more than two decades at Reckitt and now looks at healthcare through behavioural science. Gore's argument is that most companies treat health literacy as a readability job, making labels and leaflets easier to follow, when the harder work is changing what people do: helping them recognize symptoms, understand risk and act on it. We discuss the three levels of health literacy, the gap between what people intend to do and what they actually do, the line between educating and promoting, and why awareness on its own buys you almost nothing.

Timestamps 3:00 – Introductions 5:00 – What is health literacy? 7:00 – What has health literacy become so important? 15:30 – What are CHC companies doing well? 25:00 – The role of behavioural science 29:00 – What do you need to do now?

]]> 1987 no The Economic and Social Value Of Probiotics, With IPA Europe’s Rosanna Pecere The science around the microbiome is moving fast, consumers are clearly interested, and yet the category still runs into some long-standing problems in the European Union, not least the inconsistent way the word “probiotic” itself is treated across the region. In this episode of HBW Insight’s Over the Counter podcast, we talk to Rosanna Pecere, Executive Director of IPA Europe, the European office of the International Probiotics Association. Rosanna tells us about a socioeconomic assessment that the association has recently published, which tries to put a figure on what probiotics are actually worth to society. According to the report, round €10bn could be potentially saved with probiotic use, which Pecere says is probably on the conservative side. We talk about where that value comes from, from digestive and respiratory health through to mental wellbeing, and why the regulatory gap in the EU is holding so much of it back. Timestamps 2:30 – Introductions 4:00 – IPA Europe’s Socio Economic Impact Assessment 5:50 – Key Findings 8:20 – Why are probiotics so valuable? 10:00 – What is holding probiotics back? 11:00 – What would a different regulatory approach look like? 12:00 – Why should consumers care? 13:00 – What’s next? Mon, 29 Jun 2026 12:56:00 -0000 full Norstella The science around the microbiome is moving fast, consumers are clearly interested, and yet the category still runs into some long-standing problems in the European Union, not least the inconsistent way the word “probiotic” itself is treated across the region. In this episode of HBW Insight’s Over the Counter podcast, we talk to Rosanna Pecere, Executive Director of IPA Europe, the European office of the International Probiotics Association. Rosanna tells us about a socioeconomic assessment that the association has recently published, which tries to put a figure on what probiotics are actually worth to society. According to the report, round €10bn could be potentially saved with probiotic use, which Pecere says is probably on the conservative side. We talk about where that value comes from, from digestive and respiratory health through to mental wellbeing, and why the regulatory gap in the EU is holding so much of it back. Timestamps 2:30 – Introductions 4:00 – IPA Europe’s Socio Economic Impact Assessment 5:50 – Key Findings 8:20 – Why are probiotics so valuable? 10:00 – What is holding probiotics back? 11:00 – What would a different regulatory approach look like? 12:00 – Why should consumers care? 13:00 – What’s next? The science around the microbiome is moving fast, consumers are clearly interested, and yet the category still runs into some long-standing problems in the European Union, not least the inconsistent way the word “probiotic” itself is treated across the region.

In this episode of HBW Insight’s Over the Counter podcast, we talk to Rosanna Pecere, Executive Director of IPA Europe, the European office of the International Probiotics Association. Rosanna tells us about a socioeconomic assessment that the association has recently published, which tries to put a figure on what probiotics are actually worth to society.

According to the report, round €10bn could be potentially saved with probiotic use, which Pecere says is probably on the conservative side. We talk about where that value comes from, from digestive and respiratory health through to mental wellbeing, and why the regulatory gap in the EU is holding so much of it back.

Timestamps

2:30 – Introductions

4:00 – IPA Europe’s Socio Economic Impact Assessment

5:50 – Key Findings

8:20 – Why are probiotics so valuable?

10:00 – What is holding probiotics back?

11:00 – What would a different regulatory approach look like?

12:00 – Why should consumers care?

13:00 – What’s next?

]]> 965 no The Socio-Economic Case For Prevention, With Deloitte’s Elizabeth Hampson Prevention has moved to the centre of UK health policy, with the NHS 10-year plan promising a decisive shift away from treatment. The financial case for getting there is less widely understood. In this episode of the Over the Counter Podcast, HBW Insight's David Ridley speaks to Liz Hampson, life sciences and health innovation advisory partner at Deloitte, about the firm's recent work on the socioeconomic value of prevention. Hampson explains why every pound invested in prevention returns an estimated £9.20, why early intervention pays off most, and how rising out-of-pocket spending risks creating a two-tier system. The conversation also covers the gender health gap in prevention, the underused role of community pharmacy, and Hampson's argument that health literacy is where consumer health companies can make the greatest difference. Mon, 15 Jun 2026 08:55:00 -0000 full Norstella Prevention has moved to the centre of UK health policy, with the NHS 10-year plan promising a decisive shift away from treatment. The financial case for getting there is less widely understood. In this episode of the Over the Counter Podcast, HBW Insight's David Ridley speaks to Liz Hampson, life sciences and health innovation advisory partner at Deloitte, about the firm's recent work on the socioeconomic value of prevention. Hampson explains why every pound invested in prevention returns an estimated £9.20, why early intervention pays off most, and how rising out-of-pocket spending risks creating a two-tier system. The conversation also covers the gender health gap in prevention, the underused role of community pharmacy, and Hampson's argument that health literacy is where consumer health companies can make the greatest difference. Prevention has moved to the centre of UK health policy, with the NHS 10-year plan promising a decisive shift away from treatment. The financial case for getting there is less widely understood. In this episode of the Over the Counter Podcast, HBW Insight's David Ridley speaks to Liz Hampson, life sciences and health innovation advisory partner at Deloitte, about the firm's recent work on the socioeconomic value of prevention. Hampson explains why every pound invested in prevention returns an estimated £9.20, why early intervention pays off most, and how rising out-of-pocket spending risks creating a two-tier system. The conversation also covers the gender health gap in prevention, the underused role of community pharmacy, and Hampson's argument that health literacy is where consumer health companies can make the greatest difference.

]]> 1449 no How Agentic AI Changes the OTC Marketing Playbook, With IQVIA CH’s Volker Spitzer In the second part of HBW Insight’s interview with IQVIA Consumer Health’s Volker Spitzer, we turn to the commercial implications of agentic AI, and what they mean for how consumer health brands compete, communicate, and manage risk. Spitzer – vice-president, global R&D/RWE services at IQVIA Consumer Health – argues that as AI agents increasingly mediate product discovery and purchase decisions, the traditional marketing model faces a structural shift. Visibility, emotional storytelling, and share of voice do not disappear, but their influence moves upstream, into the evidence packages, product data, and formulation transparency that AI systems use to evaluate and rank products. Brands, in effect, will need to become legible to machines as well as consumers. We also chat about the uneven state of industry preparedness, the accountability questions that arise when AI recommendations cause harm, and whether the scale of current AI investment warrants caution. Spitzer closes with a realistic assessment of timelines, suggesting the full agentic model in consumer health is most likely a five-to-10-year transition, but one that companies would be unwise to treat as distant. Tue, 26 May 2026 08:26:00 -0000 full Norstella In the second part of HBW Insight’s interview with IQVIA Consumer Health’s Volker Spitzer, we turn to the commercial implications of agentic AI, and what they mean for how consumer health brands compete, communicate, and manage risk. Spitzer – vice-president, global R&D/RWE services at IQVIA Consumer Health – argues that as AI agents increasingly mediate product discovery and purchase decisions, the traditional marketing model faces a structural shift. Visibility, emotional storytelling, and share of voice do not disappear, but their influence moves upstream, into the evidence packages, product data, and formulation transparency that AI systems use to evaluate and rank products. Brands, in effect, will need to become legible to machines as well as consumers. We also chat about the uneven state of industry preparedness, the accountability questions that arise when AI recommendations cause harm, and whether the scale of current AI investment warrants caution. Spitzer closes with a realistic assessment of timelines, suggesting the full agentic model in consumer health is most likely a five-to-10-year transition, but one that companies would be unwise to treat as distant. In the second part of HBW Insight’s interview with IQVIA Consumer Health’s Volker Spitzer, we turn to the commercial implications of agentic AI, and what they mean for how consumer health brands compete, communicate, and manage risk. Spitzer – vice-president, global R&D/RWE services at IQVIA Consumer Health – argues that as AI agents increasingly mediate product discovery and purchase decisions, the traditional marketing model faces a structural shift. Visibility, emotional storytelling, and share of voice do not disappear, but their influence moves upstream, into the evidence packages, product data, and formulation transparency that AI systems use to evaluate and rank products. Brands, in effect, will need to become legible to machines as well as consumers. We also chat about the uneven state of industry preparedness, the accountability questions that arise when AI recommendations cause harm, and whether the scale of current AI investment warrants caution. Spitzer closes with a realistic assessment of timelines, suggesting the full agentic model in consumer health is most likely a five-to-10-year transition, but one that companies would be unwise to treat as distant.

]]> 1971 How Agentic AI Could Reshape Consumer Health, With IQVIA’s Volker Spitzer In the latest episode of HBW Insight's Over the Counter podcast, Volker Spitzer, vice-president, global R&D/RWE services at IQVIA Consumer Health, returns to examine the implications of agentic AI for the consumer health industry – a topic he and colleagues explore in a recently published white paper. Unlike the large language models now familiar to most consumers, agentic AI operates with persistent memory, cross-platform autonomy, and the ability to act on a user's behalf over time, functioning less like a search tool and more like a continuous personal health advisor. In the first of this two-part conversation, we discuss important questions, such as: Can AI systems can yet be trusted to guide health decisions reliably? What is the role of the pharmacist in this evolution of health information technology? Is the existing product-focused regulatory framework equipped to govern a technology that operates as a dynamic, personalized recommendation engine rather than a fixed promotional claim? Part two – published in two weeks’ time on HBW Insight – will address the commercial implications, including what the rise of agentic AI means for marketing strategy, industry readiness, and brand risk. Mon, 11 May 2026 11:18:00 -0000 full Norstella In the latest episode of HBW Insight's Over the Counter podcast, Volker Spitzer, vice-president, global R&D/RWE services at IQVIA Consumer Health, returns to examine the implications of agentic AI for the consumer health industry – a topic he and colleagues explore in a recently published white paper. Unlike the large language models now familiar to most consumers, agentic AI operates with persistent memory, cross-platform autonomy, and the ability to act on a user's behalf over time, functioning less like a search tool and more like a continuous personal health advisor. In the first of this two-part conversation, we discuss important questions, such as: Can AI systems can yet be trusted to guide health decisions reliably? What is the role of the pharmacist in this evolution of health information technology? Is the existing product-focused regulatory framework equipped to govern a technology that operates as a dynamic, personalized recommendation engine rather than a fixed promotional claim? Part two – published in two weeks’ time on HBW Insight – will address the commercial implications, including what the rise of agentic AI means for marketing strategy, industry readiness, and brand risk. In the latest episode of HBW Insight's Over the Counter podcast, Volker Spitzer, vice-president, global R&D/RWE services at IQVIA Consumer Health, returns to examine the implications of agentic AI for the consumer health industry – a topic he and colleagues explore in a recently published white paper. Unlike the large language models now familiar to most consumers, agentic AI operates with persistent memory, cross-platform autonomy, and the ability to act on a user's behalf over time, functioning less like a search tool and more like a continuous personal health advisor. In the first of this two-part conversation, we discuss important questions, such as: Can AI systems can yet be trusted to guide health decisions reliably? What is the role of the pharmacist in this evolution of health information technology? Is the existing product-focused regulatory framework equipped to govern a technology that operates as a dynamic, personalized recommendation engine rather than a fixed promotional claim? Part two – published in two weeks’ time on HBW Insight – will address the commercial implications, including what the rise of agentic AI means for marketing strategy, industry readiness, and brand risk.

]]> 1834 no